The Congressional Budget Office (CBO) has indicated that covering obesity drugs would increase the US deficit over the next ten years, with costs surpassing anticipated savings. This assessment has led to a decline in shares for major pharmaceutical companies Eli Lilly ($LLY) and Novo Nordisk ($NVO). Despite these financial concerns, Medicare is expected to negotiate the price of semaglutide, an obesity drug, in the coming years. Part D plans are preparing for the inclusion of Wegovy, another obesity drug, with strict prior authorizations anticipated to limit its use. Additionally, Medicare and Medicaid have announced coverage of anti-obesity drugs for heart patients, marking a significant policy shift. This coverage includes drugs like Wegovy for patients using them to prevent heart attacks and strokes.
Medicare can now cover certain weight loss drugs in a big step for patients https://t.co/4klXpBe8Ew
Wegovy to be covered by US Medicare for heart disease patients https://t.co/eyA7aJvuwZ https://t.co/yPxyYbE7Tg
$NVO Medicare will pay for Wegovy so long as patients are taking the drug to prevent heart attacks and strokes https://t.co/CRc34aGS8a
CMS to provide coverage of anti-obesity medication for secondary prevention of cardiovascular disease. https://t.co/Qwd1XBSpuh
Medicare and Medicaid open coverage of anti-obesity drugs for heart patients - https://t.co/bCqzIf9yux
Medicare Coverage of Zepbound, Wegovy Will Raise Federal Deficit, Official Warns https://t.co/9ANq5bDz8O
Be prepared ... #Pinksheet #pharma: Part D Plans Bracing For Wegovy; Strict Prior Authorizations To Prevent Obesity Use Are Likely https://t.co/4iOXahxEcE
Part D Plans Bracing For Wegovy; Strict Prior Authorizations To Prevent Obesity Use Are Likely https://t.co/AsPqdb9rbh #PinkSheet
How do you value obesity drug makers like $LLY and $NVO in the current market? @BMO Capital Markets Managing Director Evan David Siegerman gives us the skinny on the space and opportunities ahead: https://t.co/LXG7Izete8
Medicare will likely choose Wegovy for price negotiation "within the next few years," according to a new CBO analysis. via @john_wilkerson https://t.co/V7mA9zqXQf
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis. https://t.co/DM44NGSJzm
Eli Lilly $LLY, Novo Nordisk $NVO shares slide after CBO comments on obesity drugs https://t.co/7Nh9sEE2kE https://t.co/RiCEKQtQTc
❖ OBESITY DRUGS WOULD COST US MORE THAN ANTICIPATED SAVINGS: CBO
COVERING OBESITY DRUGS WOULD RAISE US DEFICIT OVER 10 YRS: CBO $LLY $NVO
*OBESITY DRUGS WOULD COST US MORE THAN ANTICIPATED SAVINGS: CBO $LLY $NVO